CytoDyn (STU:296) Total Operating Expense: €18.49 Mil (TTM As of Feb. 2026)


STU:296 CytoDyn Inc STU:296
27 GF Score
Price €0.19
! 1 Warning Sign
View Full Analysis

What is CytoDyn Total Operating Expense?

CytoDyn STU:296 -25.58% 27 Total Operating Expense is €18.49 Mil as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

CytoDyn's Total Operating Expense for the three months ended in Feb. 2026 was €5.33 Mil. CytoDyn's Total Operating Expense for the trailing twelve months (TTM) ended in Feb. 2026 was €18.49 Mil.

CytoDyn Total Operating Expense Related Terms

CytoDyn Total Operating Expense Historical Data

* Premium members only.

The historical data trend for CytoDyn's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn Total Operating Expense Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.68 137.75 18.35 16.70 -8.57

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.84 4.49 4.25 4.41 5.33
STU:296
27GF Score
CytoDyn Inc STU:296
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €18.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €18.49 Mil mean?
CytoDyn (STU:296) has a Total Operating Expense of €18.49 Mil as of Feb. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on CytoDyn and its competitors.
Is CytoDyn's Total Operating Expense too high?
CytoDyn's current Total Operating Expense is €18.49 Mil. Overall, CytoDyn has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Total Operating Expense compare to VSTM and IRD?
CytoDyn's Total Operating Expense of €18.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on CytoDyn and its competitors. CytoDyn's current Total Operating Expense is €18.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current Total Operating Expense of €18.49 Mil. The current Total Operating Expense is €18.49 Mil. CytoDyn's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For CytoDyn (STU:296), the current Total Operating Expense is €18.49 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
27GF Score

Get the complete analysis for STU:296

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price